Shares of Henry Schein, Inc. (NASDAQ:HSIC) have been assigned a consensus recommendation of “Hold” from the eighteen research firms that are presently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and eight have given a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $84.23.
Several analysts have recently issued reports on HSIC shares. Stifel Nicolaus reissued a “hold” rating and set a $89.00 target price on shares of Henry Schein in a report on Thursday, October 19th. Robert W. Baird set a $95.00 target price on Henry Schein and gave the stock a “buy” rating in a report on Thursday, October 19th. Jefferies Group reissued a “hold” rating and set a $89.00 target price on shares of Henry Schein in a report on Friday, October 20th. Royal Bank of Canada reduced their target price on Henry Schein from $91.00 to $82.00 and set a “sector perform” rating on the stock in a report on Tuesday, November 7th. Finally, Craig Hallum raised Henry Schein from a “hold” rating to a “buy” rating in a report on Tuesday, November 7th.
In related news, Director Barry J. Alperin sold 5,796 shares of the firm’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $70.76, for a total value of $410,124.96. Following the sale, the director now directly owns 48,172 shares of the company’s stock, valued at $3,408,650.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.19% of the company’s stock.
Shares of Henry Schein (NASDAQ:HSIC) opened at $72.18 on Tuesday. The stock has a market capitalization of $11,330.00, a price-to-earnings ratio of 20.80, a PEG ratio of 1.84 and a beta of 1.00. Henry Schein has a 1-year low of $65.28 and a 1-year high of $93.50. The company has a current ratio of 1.55, a quick ratio of 0.86 and a debt-to-equity ratio of 0.30.
COPYRIGHT VIOLATION NOTICE: “Henry Schein, Inc. (HSIC) Given Average Rating of “Hold” by Brokerages” was originally posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2018/02/13/henry-schein-inc-hsic-given-average-rating-of-hold-by-brokerages.html.
Henry Schein Company Profile
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.